CareDx and Illumina Enter Into Supply Agreement for Next Generation Sequencing Technologies

CareDx and Illumina Enter Into Supply Agreement for Next Generation Sequencing
Technologies

Agreement Expands Technology Capabilities at CareDx Reference Lab

BRISBANE, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc., a molecular
diagnostics company focused on the development and commercialization of
clinically differentiated, high value, non-invasive surveillance solutions for
transplant recipients, today announced that it has entered into a multi-year
supply agreement with Illumina, Inc. that will provide access to next
generation sequencing, microarray equipment and consumables to the CareDx
reference and R&D laboratories.

Illumina is a leading developer, manufacturer, and marketer of life science
tools and integrated systems for the analysis of genetic variation and
function.

"We're pleased to enter into this non-exclusive relationship with Illumina,
the world's leader in next generation sequencing technology," said Peter Maag,
President and CEO of CareDx. "As we expand our pipeline of high-value,
transplant diagnostic surveillance solutions from the gene expression-based
AlloMap® to cell-free DNA-based tests, we believe the technology solutions
from Illumina will effectively support our development and commercialization
efforts."

"CareDx is a recognized leader in heart transplant diagnostics, and we are
pleased to have been selected as a strategic partner to expand their
technology capabilities in the field of transplantation using next generation
sequencing," said Rick Klausner, M.D., Chief Medical Officer of Illumina.

About AlloMap®

AlloMap MolecularTesting is a non-invasive gene expression test used to aid in
the identification of heart transplant recipients who have a low probability
of moderate/severe acute cellular rejection at the time of testing in
conjunction with standard clinical assessment. AlloMap is performed in the XDx
CLIA-certified laboratory and has been commercially available in the United
States since 2005. AlloMap was cleared by the U.S. Food and Drug
Administration in 2008 and was CE marked for the European Union in 2011. Use
of AlloMap is also included in the International Society for Heart and Lung
Transplantation (ISHLT) Practice Guidelines, published in August 2010, the
worldwide standard for the care of heart transplant patients.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics
company focused on the discovery, development, and commercialization of
clinically differentiated, high-value, non-invasive gene-expression test and
surveillance solutions for transplant recipients. The company commercializes
AlloMap, which aids clinicians in identifying heart transplant recipients with
stable graft function.

For more information, please visit: www.CareDxInc.com.

CONTACT: Company
         Bradley P. Sherrill
         Senior Director, Marketing
         Tel: 415-287-2397
         bsherrill@CareDxInc.com

CareDx, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.